Article Text

Download PDFPDF
Community and primary care nursing
Statins used for secondary prevention in patients with stroke reduce the risk of further ischaemic strokes and cardiovascular events
  1. James Hill1,
  2. Marianne Hare2
  1. 1 Evidence Synthesis, University of Central Lancashire, Preston, Lancashire, UK
  2. 2 NIHR Lancashire Clinical Research Facility, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, Lancashire, UK
  1. Correspondence to Mr James Hill, Evidence synthesis, University of Central Lancashire, Preston PR1 2HE, UK; jehill1{at}uclan.ac.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: Tramacere, I, Boncoraglio, GB, Banzi, R, et al. Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. BMC Med 2019;17:67. doi:10.1186/s12916-019-1298-5.

​Implications for practice and research

  • The secondary use of statins is effective in reducing the absolute risk of ischaemic stroke and cardiac events in patients who previously have had an ischaemic stroke or transient ischaemic attack (TIA).

  • Further research is required to ascertain which statin is the most effective.

​Context

Stroke is one of the major causes of worldwide death and disability, with one in four people predicted to experience a stroke within their lifetime.1 After a stroke or a TIA, there remains a substantial long-term risk of recurrent stroke.2 It is recommended that statins should be used to reduce the risk of recurrent stroke with ischaemic stroke or TIA presumed …

View Full Text

Footnotes

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.